Replies to post #39837 on Biotech Values

[rfj1862]

RPRX

There are so many factors to take into account when valuing this company that my opinion shifts from day to day. At some point over the holidays I'll war game it to get a more realistic handle on valuation under different scenarios. Until then, it's just handwaving.

That said, I would think that $500 M+ is a reasonable expectation if the program is purchased after good results in March, agreement with the FDA that only 1 additional clinical trial is needed for Proellex in UF, and a favorable phase III plan for the endometriosis indication.

The results of the past week say to me that sometime, somewhere, Proellex will make it to market. I don't know when, at what dosage, and what the indication will say.